PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsFosamprenavir
Lexiva, Telzir(fosamprenavir)
Fosamprenavir, Telzir (fosamprenavir) is a small molecule pharmaceutical. Fosamprenavir was first approved as Lexiva on 2003-10-20. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Fosamprenavir (discontinued: Lexiva)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosamprenavir calcium
Tradename
Company
Number
Date
Products
LEXIVAViiV HealthcareN-021548 DISCN2003-10-20
1 products, RLD
LEXIVAViiV HealthcareN-022116 DISCN2007-06-14
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
fosamprenavir calciumANDA2024-07-02
lexivaNew Drug Application2020-10-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE07: Fosamprenavir
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2068227949
InfectionsD007239EFO_0000544—2282519
Acquired immunodeficiency syndromeD000163EFO_0000765B2013101519
HivD006678——1—1439
Hiv-1D015497————11—2
ProteinuriaD011507HP_0000093R80———1—1
CoinfectionD060085—————1—1
HypertriglyceridemiaD015228EFO_0004211————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Communicable diseasesD003141——114—17
Immunologic deficiency syndromesD007153HP_0002721D84.9—12—24
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———31——26
Laryngopharyngeal refluxD057045EFO_1001355——1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526—B19.21———12
Opioid-related disordersD009293EFO_0005611F111————1
TuberculosisD014376EFO_0000774A15-A191————1
MycosesD009181—B35-B491————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318HP_0001626—————22
Hepatitis bD006509——————11
Chronic hepatitis cD019698EFO_0004220B18.2————11
Chronic hepatitis bD019694EFO_0004239B18.1————11
HepatitisD006505HP_0012115K75.9————11
Hepatitis aD006506EFO_0007305B15————11
Bone fracturesD050723EFO_0003931T14.8————11
Myocardial infarctionD009203EFO_0000612I21————11
InfarctionD007238EFO_0009463—————11
Inferior wall myocardial infarctionD056989EFO_1000983—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFosamprenavir
INNfosamprenavir
Description
Fosamprenavir is a sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir. It has a role as a prodrug. It is functionally related to a sulfanilamide.
Classification
Small molecule
Drug classphosphoro-derivatives; antivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
Identifiers
PDB—
CAS-ID226700-79-4
RxCUI—
ChEMBL IDCHEMBL1664
ChEBI ID82941
PubChem CID131536
DrugBankDB01319
UNII IDWOU1621EEG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Fosamprenavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,641 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,923 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use